A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Trial Profile

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Voxilaprevir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LEPTON
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 27 Jan 2017 Results (n=53) assessing efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks, published in the Gastroenterology
    • 27 May 2016 Results published in the Gastroenterology
    • 11 May 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top